Nov 13 (Reuters) - BG Medicine Inc registerd its initial public offering of 4.5 million shares at an estimated price of $14 to $16 per share. The Waltham, Massachusetts-based molecular diagnostics company said in a filing with the U.S. Securities and Exchange Commission that Cowen & Co and Leerink Swann were underwriting the IPO.
